Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23 USD | -3.69% | +2.22% | -24.57% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-24.57% | 2.3B | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Credit Suisse Raises Intellia Therapeutics' Price Target to $101 from $98, Keeps Outperform Rating